Neuraxis (NRXS) vs Vivani Medical (VANI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neuraxis (NRXS) has outperformed Vivani Medical (VANI) over the past year, gaining 116.3% versus a loss of 10.9%. Vivani Medical is the larger company by market cap ($112.8 million vs $87.0 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRXS | VANI |
|---|---|---|
| Share price | $6.93 | $1.25 |
| Market cap | $87.03M | $112.75M |
| 1-day change | +2.36% | +1.63% |
| YTD return | +49.12% | 0.00% |
| 1-year return | +116.29% | -10.87% |
| 5-year return | — | -85.96% |
| EPS (TTM) | $-0.78 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.33 | $1.92 |
| 52-week low | $2.21 | $0.923 |
| Distance from 52-week high | -25.72% | -34.90% |
| Analyst consensus | none | none |
| Avg. price target upside | +58.73% | +206.40% |
| Average volume | 107.27K | 228.48K |
| Shares outstanding | 12.56M | 90.20M |
| Employees | 24 | 42 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXS has outperformed VANI by 127.2 percentage points over the past year.
About Neuraxis
NRXS stock →NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 24 employees
About Vivani Medical
VANI stock →Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 42 employees
NRXS vs VANI FAQ
Which is bigger, Neuraxis or Vivani Medical?
Vivani Medical (VANI) is larger, with a market capitalization of $112.75M compared with $87.03M for Neuraxis (NRXS).
Which stock has performed better over the past year, NRXS or VANI?
NRXS returned +116.29% over the past 12 months, compared with -10.87% for VANI (price return, excluding dividends). Past performance does not predict future results.
Are Neuraxis and Vivani Medical in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.